We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


IBM, Illumina Ink New Deal

IBM, Illumina Ink New Deal content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

IBM Watson Health and Illumina have announced a groundbreaking partnership to expand access to genome data interpretation by integrating Watson for Genomics into  Illumina’s BaseSpace Sequence Hub and tumor sequencing process. The collaboration is designed to help standardize and simplify genomic data interpretation.

By adding Watson for Genomics to Illumina’s next-generation  sequencing platform, researchers who use Illumina’s cancer genome sequencing  panel will have rapid access to information to help interpret the broad array  of variant data produced by TruSight Tumor 170. Illumina’s TruSight® Tumor 170 is a solid tumor profiling panel designed to detect a comprehensive set of variants across 170 genes.

In a matter of minutes, Watson for Genomics will read the genetic alteration files produced by TruSight Tumor 170, comb professional guidelines, medical literature, clinical trials compendia, and other sources of knowledge to  provide information for each genomic alteration, and produce a report for use by researchers -- a process that typically takes scientists more than one week to complete. Watson for Genomics ingests data from approximately 10,000 scientific articles and 100 new clinical trials every month.

The Watson for Genomics software will be available to support Illumina’s TruSight Tumor 170 assay early in 2017.

Cancer is a leading cause of death worldwide and a growing body of research shows that analyzing the genomic basis of a tumor can be  important for understanding the individual patient’s disease, a major aspect of  precision medicine. However, the output of next generation sequencing panels requires sophisticated analyses to help identify the mutations responsible for cancer growth and correlate that information with potential standard and experimental treatment  options. This is where Watson is expected to help.

“To enable precision cancer medicine on a large scale, we  need new tools to overcome the data barriers of genomic research,” said Francis  deSouza, President and CEO of Illumina. “With a comprehensive assay of Illumina  and the power of Watson, we hope to deliver a rapid turnaround of the genomic alteration results.”

Genome sequencing has increased in recent years following  two decades of research demonstrating the promise of precision medicine.  However, access to these advances has been limited by the significant time and  expense required to interpret the genomic data.

“This partnership lays the groundwork for more systematic  study of the impact of genomics in oncology,” said Deborah DiSanzo, general  manager, IBM Watson Health. “Together we are poised to help researchers realize the potential of precision oncology by expanding access to valuable genome sequencing from Illumina and reliable, standardized genomic interpretation from  Watson.”

Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.